We should witness changes in RDC 327, flexibility in the pharmaceutical form of products, a new resolution from CFM, but this agenda is unlikely to progress in Congress.

Deadline for submitting contributions to the proposal for the revision of RDC 327/2019 ended this Monday (2). Participation exceeded 7,000 forms

The Minas Gerais-based company, which also studies psychedelic compounds, establishes itself as one of the leading names in the sector via RDC 327

In Deusa Cast #54, Marco Fiaschetti advocates for treatment customization and the inclusion of the compounding model in the revision of RDC 327

Marcelo Mario Matos Moreira assumes as substitute in the Fourth Board, filling the vacancy of the former rapporteur of the review of RDC 327

The company, headquartered in Campinas, wants to take advantage of the path paved from RDC 327 and establish itself as an alternative in the Brazilian medicinal cannabis market with the development of studies, product launches, and, who knows, in the supply

Entity reinforces that personalized preparations are essential when industrialized products do not meet clinical needs

Group responds to public consultation and proposes changes including an increase in the THC limit and expansion of cannabinoid manipulation

Anvisa proposes exclusive process for the regulation and experts point out impact on the sector

Anvisa's proposal establishes a new regulatory framework for industrialized medicinal cannabis products in Brazil

Paula Scanapieco, commercial manager at Mile Express, explains on Deusa Cast how RDC 660 ensures access for Brazilian patients to cannabis medications through international logistics

Paula Scanapieco, commercial manager at Mile Express, explains on Deusa Cast how RDC 660 ensures access for Brazilian patients to cannabis medications through international logistics

Caroline Campagnone views RDC 999/2025 favorably, allowing veterinarians authorized by CFMV to prescribe medical cannabis

National mobilization seeks to maintain Anvisa's RDC 660/2022 and avoid risks to the continuity of treatments for thousands of patients

In Deusa Cast, experts discuss the possibility of storing cannabis-based products in Brazil. Regulatory advances, legal obstacles, and logistical impacts were debated in light of RDCs 660 and 327

In Deusa Cast, experts discuss the possibility of storing cannabis-based products in Brazil. Regulatory advances, legal hurdles, and logistical impacts were debated in light of RDCs 660 and 327

According to Marcelo Polacow Bisson, excluding pharmacies' manipulation leads to lack of assistance; Anvisa's proposed text on the Cannabis regulation is also criticized for bypassing procedural rites

Curitiba welcomes its first exclusive medicinal cannabis pharmacy, in a market that grew from R$ 38.5 million in 2022 to R$ 237.8 million in 2025, while Paraná accounts for only 2.4% of sales, indicating great potential in the state with 11 million inhabitants

Resumption of review by Anvisa and final deadline from STJ for cultivation define the sector's direction in the first quarter of the year

In an unprecedented decision, the São Paulo State Court of Justice (TJ-SP) authorized a Compounding Pharmacy to compound and dispense medicinal products and phytopharmaceuticals based on Cannabis sativa. The said decision is still subject to appeal in the higher courts.